SI1200114T1 - Inhibitorji ppar delta za zdravljenje kardiovaskularnih bolezni - Google Patents
Inhibitorji ppar delta za zdravljenje kardiovaskularnih bolezniInfo
- Publication number
- SI1200114T1 SI1200114T1 SI200031033T SI200031033T SI1200114T1 SI 1200114 T1 SI1200114 T1 SI 1200114T1 SI 200031033 T SI200031033 T SI 200031033T SI 200031033 T SI200031033 T SI 200031033T SI 1200114 T1 SI1200114 T1 SI 1200114T1
- Authority
- SI
- Slovenia
- Prior art keywords
- treatment
- cardiovascular diseases
- ppar delta
- delta inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9917405.4A GB9917405D0 (en) | 1999-07-23 | 1999-07-23 | Methods of treatment and drug screening methods |
EP00956238A EP1200114B1 (en) | 1999-07-23 | 2000-07-19 | Ppar delta inhibitors for the treatment of cardiovascular diseases |
PCT/EP2000/006986 WO2001007066A2 (en) | 1999-07-23 | 2000-07-19 | Ppar delta inhibitors for the treatment of cardiovascular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1200114T1 true SI1200114T1 (sl) | 2009-10-31 |
Family
ID=10857874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200031033T SI1200114T1 (sl) | 1999-07-23 | 2000-07-19 | Inhibitorji ppar delta za zdravljenje kardiovaskularnih bolezni |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1200114B1 (sl) |
JP (1) | JP2003505058A (sl) |
KR (1) | KR20020012323A (sl) |
CN (1) | CN1364087A (sl) |
AR (1) | AR027832A1 (sl) |
AT (1) | ATE430577T1 (sl) |
AU (1) | AU6825900A (sl) |
BR (1) | BR0012661A (sl) |
CA (1) | CA2378462A1 (sl) |
CO (1) | CO5280202A1 (sl) |
CY (1) | CY1109255T1 (sl) |
CZ (1) | CZ2002247A3 (sl) |
DE (1) | DE60042161D1 (sl) |
DK (1) | DK1200114T3 (sl) |
ES (1) | ES2326785T3 (sl) |
GB (1) | GB9917405D0 (sl) |
HK (1) | HK1046094B (sl) |
HU (1) | HUP0201966A3 (sl) |
IL (1) | IL147363A0 (sl) |
MX (1) | MXPA02000880A (sl) |
MY (1) | MY140626A (sl) |
NO (1) | NO20020326L (sl) |
NZ (1) | NZ573856A (sl) |
PL (1) | PL205747B1 (sl) |
PT (1) | PT1200114E (sl) |
SI (1) | SI1200114T1 (sl) |
TR (2) | TR200200211T2 (sl) |
WO (1) | WO2001007066A2 (sl) |
ZA (1) | ZA200200542B (sl) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL153543A0 (en) * | 2000-07-20 | 2003-07-06 | Bristol Myers Squibb Co | PHARMACEUTICAL COMPOSITIONS CONTAINING A COMPOUND WHICH INHIBITS OR MODULATES PPARdelta (beta) ACTIVITY |
EP1357914A2 (en) * | 2001-02-02 | 2003-11-05 | SmithKline Beecham Corporation | Treatment of ppar mediated diseases |
GB0103809D0 (en) | 2001-02-16 | 2001-04-04 | Univ Dundee | Methods |
AU2003220521A1 (en) * | 2002-03-27 | 2003-10-13 | Smithkline Beecham Corporation | Methods of treatment with lxr modulators |
GB0302446D0 (en) * | 2003-02-03 | 2003-03-05 | Imp College Innovations Ltd | Screening for modulators of fat storage |
EP1637161A4 (en) * | 2003-04-22 | 2007-06-27 | Astellas Pharma Inc | MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST |
US20070237740A1 (en) * | 2004-09-27 | 2007-10-11 | Vical, Inc. | Formulations and Methods for Treatment of Inflammatory Diseases |
DE102006033394A1 (de) * | 2006-07-13 | 2008-01-17 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Verfahren zum Auffinden von antiatherosklerotischen Substanzen |
WO2008084962A1 (en) * | 2007-01-08 | 2008-07-17 | Seoul National University Industry Foundation | THIAZOLE COMPOUND (AS PPARδ) LIGAND AND PHARMACEUTICAL, COSMETIC AND HEALTH FOOD COMPRISED THEREOF |
CN112168820B (zh) * | 2019-07-05 | 2023-09-29 | 中国科学院生物物理研究所 | SRCAP ATPase抑制剂在结直肠癌治疗中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
US5939442A (en) * | 1995-06-07 | 1999-08-17 | The Salk Institute For Biological Studies | Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof |
AU1856997A (en) * | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
JP3076066B2 (ja) * | 1996-08-27 | 2000-08-14 | 塩野義製薬株式会社 | クロメン−3−カルボン酸誘導体 |
WO1998025598A2 (en) * | 1996-12-11 | 1998-06-18 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumour cell growth |
AU6773598A (en) * | 1997-03-26 | 1998-10-20 | Institut Pasteur | Treatment of gastrointestinal disease with ppar modulators |
AU8038698A (en) * | 1997-06-27 | 1999-01-19 | Ono Pharmaceutical Co. Ltd. | Novel plasmid dna containing reporter gene dna and use of the same |
ATE421336T1 (de) * | 1997-07-24 | 2009-02-15 | Astellas Pharma Inc | Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
-
1999
- 1999-07-23 GB GBGB9917405.4A patent/GB9917405D0/en not_active Ceased
-
2000
- 2000-07-19 MX MXPA02000880A patent/MXPA02000880A/es unknown
- 2000-07-19 CZ CZ2002247A patent/CZ2002247A3/cs unknown
- 2000-07-19 DK DK00956238T patent/DK1200114T3/da active
- 2000-07-19 DE DE60042161T patent/DE60042161D1/de not_active Expired - Lifetime
- 2000-07-19 KR KR1020027000942A patent/KR20020012323A/ko not_active Application Discontinuation
- 2000-07-19 IL IL14736300A patent/IL147363A0/xx unknown
- 2000-07-19 CN CN00810779A patent/CN1364087A/zh active Pending
- 2000-07-19 PT PT00956238T patent/PT1200114E/pt unknown
- 2000-07-19 NZ NZ573856A patent/NZ573856A/en unknown
- 2000-07-19 EP EP00956238A patent/EP1200114B1/en not_active Expired - Lifetime
- 2000-07-19 BR BR0012661-6A patent/BR0012661A/pt not_active Application Discontinuation
- 2000-07-19 AT AT00956238T patent/ATE430577T1/de active
- 2000-07-19 SI SI200031033T patent/SI1200114T1/sl unknown
- 2000-07-19 ES ES00956238T patent/ES2326785T3/es not_active Expired - Lifetime
- 2000-07-19 JP JP2001511949A patent/JP2003505058A/ja active Pending
- 2000-07-19 TR TR2002/00211T patent/TR200200211T2/xx unknown
- 2000-07-19 PL PL364749A patent/PL205747B1/pl not_active IP Right Cessation
- 2000-07-19 TR TR2005/01763T patent/TR200501763T1/xx unknown
- 2000-07-19 CA CA002378462A patent/CA2378462A1/en not_active Abandoned
- 2000-07-19 AU AU68259/00A patent/AU6825900A/en not_active Abandoned
- 2000-07-19 WO PCT/EP2000/006986 patent/WO2001007066A2/en not_active Application Discontinuation
- 2000-07-19 HU HU0201966A patent/HUP0201966A3/hu not_active Application Discontinuation
- 2000-07-21 CO CO00054777A patent/CO5280202A1/es not_active Application Discontinuation
- 2000-07-21 MY MYPI20003340A patent/MY140626A/en unknown
- 2000-07-21 AR ARP000103776A patent/AR027832A1/es unknown
-
2002
- 2002-01-22 ZA ZA200200542A patent/ZA200200542B/en unknown
- 2002-01-22 NO NO20020326A patent/NO20020326L/no not_active Application Discontinuation
- 2002-10-22 HK HK02107665.7A patent/HK1046094B/zh not_active IP Right Cessation
-
2009
- 2009-07-15 CY CY20091100754T patent/CY1109255T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL362711A1 (en) | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | |
HK1047284A1 (en) | 2-amino-benzoxazinone derivatives for the treatment of obesity | |
GB0010669D0 (en) | Compositions for treatment of disorders of the oesophagus | |
HUP0402629A3 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
HUP0102295A3 (en) | Benzamide derivatives for the treatment of diseases mediated by cytokines | |
GB2351661B (en) | Novel method of treatment | |
HUP0102367A3 (en) | Benzamide derivatives for the treatment of diseases mediated by cytokines | |
IL145875A0 (en) | Novel method of treatment | |
HK1053058A1 (zh) | 普拉克索用於治療成癮性疾病的用途 | |
HK1046094B (zh) | 治療心血管疾病的PPARδ抑制劑 | |
HUP0200738A3 (en) | Method of the treatment of incontinence | |
AU2001267404A1 (en) | Novel compounds for the treatment of inflammatory and cardiovascular diseases | |
IL155769A0 (en) | Method for the treatment of inflammation | |
GB9924087D0 (en) | Treatment of process fluids | |
ZA200110539B (en) | Oxazinocarbazoles for the treatment of CNS diseases. | |
CZ20011872A3 (cs) | Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny | |
HUP0001891A2 (en) | Medicament for the treatment of migraine | |
GB9930688D0 (en) | Novel method of treatment | |
SI1200447T1 (sl) | Oksazinokarbazoli za zdravljenje CNS bolezni | |
GB9926985D0 (en) | Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and-cyanamides for the treatment of diseases | |
SI1183046T1 (sl) | Derivat aminotetralina za terapijo kardiovaskularnih bolezni | |
GB9930696D0 (en) | Novel method of treatment | |
SI1150704T1 (sl) | Melagatran za zdravljenje vnetja | |
GB9924275D0 (en) | Method for the treatment of obesity |